?Here I am just sitting in this house and I?m able to predict a cure to measles,? co-founder of Atomwise Alex Levy tells me over the phone from his apartment in Mountain View, Calif.
Atomwise, a health tech startup in the current Y Combinator batch, has launched more than a dozen projects in the last year to find cures for both common and orphan diseases ? diseases that would otherwise be too expensive and time-intensive to tackle. It?s working with IBM to find a cure to Ebola and with Dalhousie University in Canada to search for a measles treatment. Levy says the startup went through 8.2 million compounds to find potential cures for multiple sclerosis in a matter of days.
It takes an average of 12 years and about $2.9 billion to put new drugs on the market. On top of that, very few experimental drugs ever see the medicine cabinet (1 in every 5,000 drugs moves on to human trials).
?Here I am just sitting in this house and I?m able to predict a cure to measles,? co-founder of Atomwise Alex Levy tells me over the phone from his apartment in Mountain View, Calif.
Atomwise, a health tech startup in the current Y Combinator batch, has launched more than a dozen projects in the last year to find cures for both common and orphan diseases ? diseases that would otherwise be too expensive and time-intensive to tackle. It?s working with IBM to find a cure to Ebola and with Dalhousie University in Canada to search for a measles treatment. Levy says the startup went through 8.2 million compounds to find potential cures for multiple sclerosis in a matter of days.
It takes an average of 12 years and about $2.9 billion to put new drugs on the market. On top of that, very few experimental drugs ever see the medicine cabinet (1 in every 5,000 drugs moves on to human trials).
Read more at Tech Crunch.?
